Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

259
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
259
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

301
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
301
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.9K
ATP Synthase: Mechanism01:48

ATP Synthase: Mechanism

15.0K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
15.0K
Mitochondrial Membranes01:45

Mitochondrial Membranes

11.8K
A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
11.8K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

224
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
224

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Scapular belt for the treatment of comminuted fractures of scapula].

Zhongguo gu shang = China journal of orthopaedics and traumatology·2010
Same author

Manipulation of ordered nanostructures of protonated polyoxometalate through covalently bonded modification.

Chemistry (Weinheim an der Bergstrasse, Germany)·2010
Same author

Developments in nonsteroidal antiandrogens targeting the androgen receptor.

ChemMedChem·2010
Same author

Dynamic presentation of immobilized ligands regulated through biomolecular recognition.

Journal of the American Chemical Society·2010
Same author

[Research on crop-weed discrimination using a field imaging spectrometer].

Guang pu xue yu guang pu fen xi = Guang pu·2010
Same author

A palladium/copper bimetallic catalytic system: dramatic improvement for Suzuki-Miyaura-type direct C-H arylation of azoles with arylboronic acids.

Chemistry (Weinheim an der Bergstrasse, Germany)·2010

Related Experiment Video

Updated: Aug 15, 2025

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

11.8K

Mitochondrial dysfunction in pulmonary arterial hypertension.

Weiwei Zhang1, Bo Liu2, Yazhou Wang3

  • 1Department of Oncology, Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People's Hospital (The Second Clinical Medical College Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine), Chengdu, China.

Frontiers in Physiology
|January 2, 2023
PubMed
Summary

Pulmonary arterial hypertension (PAH) involves mitochondrial dysfunction, impacting blood vessels. Understanding these metabolic changes may lead to new PAH treatments.

Keywords:
mitochondrial dysfunctionmitochondrial metabolismpulmonary arterial hypertensionpulmonary vascular remodelingpulmonary vasoconstriction

More Related Videos

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

1.7K
Author Spotlight: Exploring Mitochondrial Function and Chemical Toxicity Using Drosophila melanogaster
09:20

Author Spotlight: Exploring Mitochondrial Function and Chemical Toxicity Using Drosophila melanogaster

Published on: November 10, 2023

1.0K

Related Experiment Videos

Last Updated: Aug 15, 2025

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

11.8K
Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

1.7K
Author Spotlight: Exploring Mitochondrial Function and Chemical Toxicity Using Drosophila melanogaster
09:20

Author Spotlight: Exploring Mitochondrial Function and Chemical Toxicity Using Drosophila melanogaster

Published on: November 10, 2023

1.0K

Area of Science:

  • Cardiovascular Research
  • Metabolic Medicine
  • Pulmonary Hypertension Pathophysiology

Background:

  • Pulmonary arterial hypertension (PAH) is a severe condition with high mortality and limited treatment options.
  • Current understanding of PAH pathogenesis is incomplete, with metabolic factors emerging as critical.
  • Mitochondrial dysfunction is increasingly implicated in PAH development and progression.

Purpose of the Study:

  • To elucidate the intricate relationship between mitochondrial metabolism and PAH.
  • To explore how metabolic alterations contribute to pulmonary vasoconstriction and vascular remodeling in PAH.
  • To identify potential therapeutic targets within mitochondrial pathways for PAH treatment.

Main Methods:

  • Review of recent scientific literature on mitochondrial metabolism and PAH.
  • Analysis of studies linking mitochondrial dysfunction to key PAH mechanisms.
  • Synthesis of evidence on metabolic pathways involved in pulmonary vascular changes.

Main Results:

  • Mitochondrial dysfunction affects the tricarboxylic acid cycle, redox balance, and energy production in PAH.
  • Altered glycolysis, increased reactive oxygen species, and calcium dysregulation are linked to PAH.
  • Mitophagy impairment contributes to the progression of pulmonary vascular disease.

Conclusions:

  • Mitochondrial metabolism plays a crucial role in the pathogenesis of pulmonary arterial hypertension.
  • Targeting mitochondrial dysfunction offers a promising avenue for developing novel PAH therapies.
  • Further research into these metabolic mechanisms could lead to more effective and specific treatments for PAH patients.